KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks
RSI low/high Values: [ 20 - 80 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of HIK.L
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Green day on Friday for Hikma Pharmaceuticals Plc
(Updated on Apr 26, 2024)

Buy candidate since Apr 25, 2024 Gain 3.18% PDF

The Hikma Pharmaceuticals Plc stock price gained 3.18% on the last trading day (Friday, 26th Apr 2024), rising from £1,854.00 to £1,913.00. During the last trading day the stock fluctuated 3.17% from a day low at £1,861.00 to a day high of £1,920.00. The price has risen in 7 of the last 10 days and is up by 6.1% over the past 2 weeks. Volume fell on the last day by -267 thousand shares and in total, 370 thousand shares were bought and sold for approximately £707.60 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -7.42% during the next 3 months and, with a 90% probability hold a price between £1,625.93 and £1,824.78 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

HIK.L Signals & Forecast

Mostly positive signals in the chart today. The Hikma Pharmaceuticals Plc stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections down, there will be some support from the lines at £1,829.29 and £1,855.67. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Wednesday, April 17, 2024, and so far it has risen 7.84%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. The stock had a Golden Star Signal on Monday, January 29, 2024 in the long-term chart.

Golden Star Signal is when the short-term moving average, the long-term moving average, and price line meet in a special combination. This combination is very rare and often followed by long and strong gains for the stock in question.

Buy
Special Signal Notification

Golden Star 12 Months

The stock had a Golden Star Signal on Monday, January 29, 2024 in the long-term chart.

Golden Star Signal is when the short-term moving average, the long-term moving average, and price line meet in a special combination. This combination is very rare and often followed by long and strong gains for the stock in question.

Support, Risk & Stop-loss for Hikma Pharmaceuticals Plc stock

Hikma Pharmaceuticals Plc finds support from accumulated volume at £1,883.00 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock is usually traded at a good volume, and with minor daily changes, the risk is considered to be low. During the last day, the stock moved £59.00 (3.17%) between high and low. For the last week, the stock has had daily average volatility of 2.88%.

Our recommended stop-loss: £1,851.02 (-3.24%) (This stock has low daily movements and this gives low risk. There is a buy signal from a pivot bottom found 7 days ago.)

Trading Expectations (HIK.L) For The Upcoming Trading Day Of Monday 29th

For the upcoming trading day on Monday, 29th we expect Hikma Pharmaceuticals Plc to open at £1,898.00, and during the day (based on 14 day Average True Range), to move between £1,866.95 and £1,959.05, which gives a possible trading interval of +/-£46.05 (+/-2.41%) up or down from last closing price. If Hikma Pharmaceuticals Plc takes out the full calculated possible swing range there will be an estimated 4.81% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at £1,939.50 (1.39%) than the support at £1,883.00 (1.57%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Hikma Pharmaceuticals Plc stock A Buy?

Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for stock to perform well in the short-term.

Current score: 2.039 Buy Candidate Unchanged

Predicted Opening Price for Hikma Pharmaceuticals Plc of Monday, April 29, 2024

Fair opening price April 29, 2024 Current price
£1,898.00 ( 0.784%) £1,913.00

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for HIK.L

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 1,957.00 2.30 %
R2 1,934.46 1.12 %
R1 1,920.54 0.394 %
Current price: 1,913.00
Support S1 1,875.46 -1.96 %
S2 1,861.54 -2.69 %
S3 1,839.00 -3.87 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 2,083.00 8.89 %
R2 1,994.00 4.23 %
R1 1,939.50 1.39 %
Current price 1,913.00
Support S1 1,883.00 -1.57%
S2 1,855.50 -3.01%
S3 1,847.00 -3.45%

HIK Dividend Payout History


# Declaration Date Ex-Date Pay Date Amount Yield
1 Mar 21, 2024 Mar 21, 2024 May 03, 2024 £37.07 1.94%
2 Feb 23, 2023 Mar 23, 2023 May 05, 2023 £29.52 1.58%
3 Aug 04, 2022 Aug 18, 2022 Sep 19, 2022 £16.00 1.28%
4 Feb 24, 2022 Mar 17, 2022 Apr 28, 2022 £26.00 1.28%
5 Aug 06, 2021 Aug 19, 2021 Sep 20, 2021 £13.00 0.545%

FAQ

What is the symbol for Hikma Pharmaceuticals Plc Stock and on which exchange is it traded?
The symbol for Hikma Pharmaceuticals Plc is HIK.L and it is traded on the XLON (London Stock Exchange).

Should I buy or sell Hikma Pharmaceuticals Plc Stock?
Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for stock to perform well in the short-term.

How to buy Hikma Pharmaceuticals Plc Stock?
Hikma Pharmaceuticals Plc Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Hikma Pharmaceuticals Plc Stock.

What's the current price of Hikma Pharmaceuticals Plc Stock?
As of the end of day on the Apr 26, 2024, the price of an Hikma Pharmaceuticals Plc (HIK.L) share was £1,913.00.

What is the 52-week high and low for Hikma Pharmaceuticals Plc Stock?
The 52-week high for Hikma Pharmaceuticals Plc Stock is £2,222.00 and the 52-week low is £1,711.00.

What is the market capitalization of Hikma Pharmaceuticals Plc Stock?
As of the Apr 26, 2024, the market capitalization of Hikma Pharmaceuticals Plc is 4.114B.

When is the next earnings date for Hikma Pharmaceuticals Plc?
The upcoming earnings date for Hikma Pharmaceuticals Plc is Aug 08, 2024.
Click to get the best stock tips daily for free!

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Plc Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-in... HIK.L Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT